

We would like to ask each of you to pay particular attention to specific components of the consortium during the meeting:

- \* Paula Hammoud, Jonathan Sweedler - Transformative Technology Development projects
- \* Andrea de Souza, Jason Swedlow - HIVE components
- \* Stephen Hewitt, Joe Gray – Tissue Mapping Centers
- \* Junhyong Kim - Rapid Technology Implementation projects

and ask that you think about the following questions during the meeting:

- \* Junhyong Kim – can the consortium realistically integrate data from different regions of the body, across individuals and across the different sites / assays using the currently proposed methods? is there sufficient planning for optimizing data collection based on what is needed for modelling, and for feedback to optimize future data collection? Are plans for sequencing data analysis sufficiently developed?
- \* Stephen Hewitt – is the consortium approaching tissue collection, pre-processing and metadata collection in an appropriate way? what tissues / kinds of tissue mapping are missing from the consortium and should be treated as priorities? (e.g. analysis on multiple organs from the same donor?)
- \* Joe Gray – is there sufficient synergy between the assays being used by the TMCs that would enable joint analysis? are there combinations of assays that would be valuable but are missing from current work? is there tangible progress on the collaborative projects between funded groups? Are plans for imaging data analysis sufficiently developed?
- \* Jason Swedlow – are there gaps or challenges with how the consortium is thinking about data release? Are there sufficient plans for making data and other resources FAIR? Are plans for imaging data analysis sufficiently developed? Will the data portal have sufficient features for a first data release?
- \* Paula Hammoud – does the consortium have significant use cases in mind when it is generating and analyzing data? are the research resources / products being generated by the consortium likely to be useful by: 1) other similar consortia, 2) wider research community? Where are there opportunities for wider collaboration and coordination?
- \* Jonathan Sweedler – are there emerging technologies or obvious technology gaps that the consortium should prioritize? How critical is it for the consortium to better understand the extracellular environment and functional modification of biomolecules? Are plans for mass spec data analysis sufficiently developed?
- \* Andrea de Souza – what would lead to a more cohesive consortium? are there communication gaps, a sense of common purpose or valuable activities among current efforts? what is missing?
- \* Bonus question for everyone: do you believe the consortium will be in a position to release a meaningful set of data by Summer 2020?